Codex Biosolutions, Inc. is an advanced biotechnology company headquartered in the state of Maryland. We offer simple and high throughput solutions to aid scientists in solving complex problems. One of our primary focuses is on drug discovery. We are a leader in providing live cell based assays for novel compound screening. Our patented ACTOne based phosphodiesterase (PDE) and G-protein coupled receptor (GPCR) cell lines offer clients the ability to conduct efficient screenings of new compounds in a physiologically accurate, live cell based environment. We are the first in the world to produce commercially available cell lines to screen for compounds that target PDEs. We also provide a number of unique biochemical assay kits and specialty dyes. We strive to deliver high quality products that help our fellow scientists in the discovery process.
In the past five years, Codex participated in Tox21, a federal Collaboration involving the NIH, EPA and FDA. We developed assays for nuclear hormone receptors, dye based mitochondria toxicity assays. Now, we are developing the assays to evaluate the toxicities on TSHR and TRHR.